

# SOTAC PHARMACEUTICALS LIMITED

(Formerly Known as, Sotac Pharmaceuticals Private Limited)



**Registered Office :**

Plot No.: PF/21, Nr. Acme Pharma,  
Opp. Teva Pharma, Sanand GIDC - II,  
Sanand, Ahmedabad - 382110. Gujarat (INDIA)  
**CIN No.: L24230GJ2015PLC085451**

**Date: October 29, 2024**

**To,**  
**Listing Compliance Department**  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex  
Bandra East, Mumbai-400051

**Dear Sir/Ma'am,**

**Sub: Outcome of Board Meeting held today i.e. on October 29, 2024 in terms of second proviso to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)**

In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held today, i.e. on Tuesday, October 29, 2024, at the Registered Office of the Company situated at Plot No. PF-21, Nr. Acme Pharma, Opp. Teva Pharma, Sanand GIDC-II, Sanand, Ahmedabad- 382110, which was commenced at 03:30 P.M. and concluded at 04:00 P.M., to have;

1. Considered, approved and taken on record the Unaudited Standalone and Consolidated financial result of the Company for the Half year ended on September 30, 2024,
2. Approved the Limited Review Report issued by Statutory Auditors of the Company for the Half year ended on September 30, 2024,
3. Statement of Assets and Liabilities,
4. Cash Flow Statement,
5. Considered and approved all other business as per agenda circulated.

Further, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are enclosing herewith the Standalone and Consolidated Unaudited Financial Results for the Half year ended September 30, 2024 and Limited Review Report issued by Statutory Auditors on the Standalone and Consolidated Unaudited Financial results for the half year ended on September 30, 2024.

Kindly take the same on your records.

Thanking you.

Yours faithfully,

**For, Sotac Pharmaceuticals Limited**

A handwritten signature in black ink, appearing to read "Sharadkumar".

**Sharadkumar Dashrathbhai Patel**  
**Chairman and Managing Director**  
**DIN: 07252252**



**Place: Ahmedabad**

**Contact No.: 99135 62852, 87994 83159, 99250 45971**



**www.sotacpharma.com**



**sotacpharma@gmail.com**

# SOTAC PHARMACEUTICALS LIMITED

(Formerly Known as, Sotac Pharmaceuticals Private Limited)



**Registered Office :**

Plot No.: PF/21, Nr. Acme Pharma,  
Opp. Teva Pharma, Sanand GIDC - II,  
Sanand, Ahmedabad - 382110. Gujarat (INDIA)  
**CIN No.: L24230GJ2015PLC085451**

**Date: October 29, 2024**

To,  
**Listing Compliance Department**  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex  
Bandra East, Mumbai-400051.

**Dear Sir/Ma'am,**

**Subject: Submission of Unaudited Standalone and Consolidated Financial Result of the Company for the Half year ended on September 30, 2024 along with Limited Review Report.**

**Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)**

In reference to captioned subject and pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the Half year ended on September 30, 2024 along with Limited Review Report issued by Statutory Auditors on the Unaudited Standalone and Consolidated Financial Results for the Half year ended on September 30, 2024.

Kindly take the above on your records.

Thanking You,

Yours faithfully,

**For, Sotac Pharmaceuticals Limited**

A handwritten signature in black ink, appearing to read "Sharadkumar".

**Sharadkumar Dashrathbhai Patel**  
**Chairman and Managing Director**  
**DIN: 07252252**



**Place: Ahmedabad**

**Encl: - A/a**

**Contact No.: 99135 62852, 87994 83159, 99250 45971**



**www.sotacpharma.com**



**sotacpharma@gmail.com**





**Auditor's Limited Review Report on unaudited Standalone Financial results of Sotac Pharmaceutical Limited, for the Half year ended September 30, 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

To,  
The Board of Directors of,  
Sotac Pharmaceutical Limited

We have reviewed the accompanying the statement of unaudited Standalone financial results of **Sotac Pharmaceutical Limited** for the half year ended September 30, 2024. The Financial Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this financial statement based on the review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primary to inquire of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results prepared in accordance with applicable standards and other recognized accounting practices and policies has not disclosed the information require to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Keyur Shah & Co.  
Chartered Accountants  
F.R.No. 141173W



Keyur Shah  
Proprietor  
M. No. 153774  
UDIN: -24153774BKBOFQ7212

Date: - 29/10/2024  
Place: - Ahmedabad

**SOTAC PHARMACEUTICALS LIMITED**  
(Formerly known as Sotac Pharmaceuticals Private Limited)  
Plot No PF-21, Nr. ACME Pharma, Opp. Teva Pharma, Sanand GIDC-II, Ahmedabad-382110  
UNAUDITED STANDALONE FINANCIAL RESULT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2024


(INR in Lakhs unless otherwise Specified)

Sr no.	Particulars	Half year ended		Year ended	
		30.09.24 Unaudited	31.03.24 Audited	30.09.23 Unaudited	31.03.24 Audited
I)	REVENUE FROM OPERATIONS	3,061.42	3,399.25	3,311.25	6,710.50
II)	OTHER INCOME	92.25	79.91	51.96	131.87
III)	<b>TOTAL REVENUE ( I + II )</b>	<b>3,153.67</b>	<b>3,479.16</b>	<b>3,363.21</b>	<b>6,842.37</b>
IV)	<b>EXPENSES</b>				
a)	Cost of Material Consumed	2,002.95	2,204.70	2,006.10	4,210.80
b)	Purchase of Stock-in-Trade	71.76	169.32	92.26	261.58
c)	Changes in Inventories of Finished Goods/ Work-In-Progress/ Stock in Trade	133.21	(20.85)	68.46	47.61
d)	Employee Benefit Expenses	97.97	122.14	143.54	265.68
e)	Finance Costs	49.58	47.84	53.50	101.34
f)	Depreciation and Amortisation Expense	119.98	141.37	109.74	251.11
g)	Other Expenses	393.94	399.39	505.97	905.36
	<b>TOTAL EXPENSES (IV)</b>	<b>2,869.39</b>	<b>3,063.91</b>	<b>2,979.57</b>	<b>6,043.48</b>
V)	<b>PROFIT/(LOSS) BEFORE EXCEPTIONAL &amp; EXTRAORDINARY ITEMS &amp; TAX (III - IV)</b>	<b>284.28</b>	<b>415.25</b>	<b>383.64</b>	<b>798.89</b>
VI)	Exceptional/Prior Period Items	(0.04)	(23.38)	-	(23.38)
VII)	<b>PROFIT BEFORE EXTRAORDINARY ITEMS &amp; TAX (V-VI)</b>	<b>284.24</b>	<b>391.87</b>	<b>383.64</b>	<b>775.51</b>
IX)	<b>PROFIT BEFORE TAX ( VII-VIII)</b>	<b>284.24</b>	<b>391.87</b>	<b>383.64</b>	<b>775.51</b>
X)	<b>TAX EXPENSE</b>				
a)	Current Tax	76.10	115.38	97.26	212.64
b)	Deferred Tax	(3.50)	(7.10)	(1.12)	(8.22)
c)	Income Tax Excess Provisions Related to Earlier Years	-	(3.79)	-	(3.79)
	<b>TOTAL TAX EXPENSE (X)</b>	<b>72.60</b>	<b>104.49</b>	<b>96.14</b>	<b>200.63</b>
XI)	<b>PROFIT / (LOSS) FOR THE PERIOD/YEAR (IX-X)</b>	<b>211.64</b>	<b>287.38</b>	<b>287.50</b>	<b>574.88</b>
XII)	Paid up Equity Share Capital (Face value Rs 10 each)	1105.00	1105.00	1105.00	1105.00
XIII)	Reserve & Surplus (Excluding Revaluation Reserve)				3722.44
XIII)	<b>EARNINGS PER EQUITY SHARE-BASIC/DILUTED</b>				
	Basic /Diluted earnings per share (In INR) (not annualised, for the Half year ended)	1.92	2.60	2.64	5.24

**Notes:**

- [1] The standalone unaudited financial results are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable.
- [2] The above standalone unaudited financial results for the Half year ended September 30, 2024 have been prepared by the Company in accordance with Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on October 29, 2024, A limited review of the above results has been carried out by the statutory auditors of the company.
- [3] The figures for the Half year ended 31st March 2024 are the Balancing figures between the audited figures in respect of full financial year and the audited figures in respect of first Half of the Financial year 2023-24.
- [4] The figures of the previous period have been re-grouped / rearranged and / or recasted wherever considered necessary.
- [5] Company is mainly engaged in manufacturing of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment, hence segment reporting is not applicable to Company.
- [6] The Status of investor's complaints during the Half year ended on September 30, 2024 as under:-

Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed during the period	Nil
Complaints resolved at the end of the period	Nil



For & on behalf of Sotac Pharmaceuticals Limited

*Sharad Patel*  
Sharad Patel  
Chairman & Managing Director  
Din No-07252252

Place : Ahmedabad  
Date : 29th October, 2024



**SOTAC PHARMACEUTICALS LIMITED**  
(Formerly known as Sotac Pharmaceuticals Private Limited)  
Plot No PF-21, Nr. ACME Pharma, Opp. Teva Pharma, Sanand GIDC-II, Ahmedabad-382110  
Unaudited Standalone Balance Sheet as at 30th September, 2024


(INR in lakhs, unless otherwise stated)

Particulars	As at 30th September '24	As at 31st March '24
<b>I. EQUITY AND LIABILITIES</b>		
<b>(1) Shareholder's Funds</b>		
(a) Share Capital	1,105.00	1,105.00
(b) Reserves And Surplus	3,933.25	3,722.44
<b>Total Equity</b>	<b>5,038.25</b>	<b>4,827.44</b>
<b>(2) Share Application Money Pending Allotment</b>		
	-	-
<b>(3) Non-Current Liabilities</b>		
(a) Long-Term Borrowings	376.35	440.94
(b) Long Term Provisions	15.76	12.37
<b>Total Non-Current Liabilities</b>	<b>392.11</b>	<b>453.31</b>
<b>(4) Current Liabilities</b>		
(a) Short-Term Borrowings	673.20	675.67
(b) Trade Payable		
i) Total outstanding dues of micro enterprise and small enterprise	1,158.24	615.13
ii) Total outstanding dues other than micro enterprise and small enterprise	803.19	859.85
(c) Other Current Liabilities	183.84	100.32
(d) Short-Term Provisions	129.79	76.83
<b>Total Current Liabilities</b>	<b>2,948.26</b>	<b>2,327.80</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>8,378.62</b>	<b>7,608.55</b>
<b>II. ASSETS</b>		
<b>(1) Non-Current Assets</b>		
(a) Property, Plant & Equipment & Intangible Assets		
(i) Property, Plant & Equipment	1,695.93	1,765.43
(ii) Intangible Assets	2.37	1.30
(iii) Capital Work In -Progress	4.54	4.77
(b) Non-Current Investments	1,553.34	1,149.82
(c) Deferred Tax Assets (Net)	16.12	12.62
<b>Total Non-Current Assets</b>	<b>3,272.30</b>	<b>2,933.94</b>
<b>(2) Current Assets</b>		
(a) Inventories	965.49	1,102.33
(b) Trade Receivables	2,324.94	2,201.23
(c) Cash and Cash Equivalents	23.36	64.17
(d) Short-Term Loans And Advances	1,118.38	716.80
(e) Other Current Assets	674.15	590.08
<b>Total Current Assets</b>	<b>5,106.32</b>	<b>4,674.61</b>
<b>TOTAL ASSETS</b>	<b>8,378.62</b>	<b>7,608.55</b>

For, Sotac Pharmaceuticals Limited



Sharad Patel  
(Chairman & Managing Director)  
Din No-07252252



Place: Ahmedabad  
Date: 29th October, 2024

**SOTAC PHARMACEUTICALS LIMITED**  
(Formerly known as Sotac Pharmaceuticals Private Limited)  
Plot No PF-21, Nr. ACME Pharma, Opp. Teva Pharma, Sanand GIDC-II, Ahmedabad-382110  
Unaudited Standalone Cash Flow Statement For The Half Year Ended on 30th September '24

(Amount in Lakhs)

Particulars	As at 30th September '24	As at 30th September '23
<b>Cash Flow from Operating Activities</b>		
Net Profit Before Tax Paid	284.24	383.64
<b>Adjustments for :</b>		
Depreciation And Amortization	119.98	109.74
Interest Income	(62.58)	(50.04)
Finance Cost	49.58	53.50
Provision for Gratuity	2.44	1.60
Adjustment Related to IPO Expnese and Deffered Government Grants	(0.83)	(228.59)
<b>Operating Profit Before Working Capital Changes (a)</b>	<b>392.83</b>	<b>269.85</b>
<b>Adjustment For Changes In Working Capital :</b>		
Changes In Trade Payables	486.45	(544.53)
Changes In Other Current Liabilities	83.52	(233.64)
Changes In Short term Provisions	(3.83)	(2.66)
Changes In Inventories	136.84	(29.35)
Changes In Trade Receivables	(123.71)	(489.26)
Changes In Short Term Loans and Advances	(401.58)	(0.80)
Changes In Other Current Assets	(84.07)	(57.56)
<b>(b)</b>	<b>93.62</b>	<b>(1,357.80)</b>
<b>Cash Generated From Operations (a + b)</b>	<b>486.45</b>	<b>(1,087.95)</b>
Taxes Paid ( Net Of Refund)	(18.35)	(159.47)
<b>Net Cash Generated From Operations (A)</b>	<b>468.10</b>	<b>(1,247.42)</b>
<b>Cash Flow From Investing Activities</b>		
Addition In Propery, Plant and Equipments And Intagible Assets	(51.76)	(508.58)
Disposals Of Propery, Plant and Equipments And Intagible Assets	0.43	-
Addition In Capital Work In Progress	-	(0.71)
Changes In Non Current Investment	(403.52)	(510.00)
Interest Income	62.58	50.04
<b>Net Cash Generated / ( Used ) in Investing Activities (B)</b>	<b>(392.27)</b>	<b>(969.25)</b>
<b>Cash Flow From Financing Activities</b>		
Proceeds From Issue of Equiry Share	-	300.00
Proceeds From Securities Premium	-	3,030.00
Proceeds From Share Application Money Received	-	(947.05)
Short term Advances	-	(1,130.00)
Changes In Long Term Borrowings	(64.59)	(53.86)
Changes In of Short Borrowings	(2.47)	126.59
Finance Cost	(49.58)	(53.50)
<b>Net Cash Used In Financing Activities (C)</b>	<b>(116.64)</b>	<b>1,272.18</b>
<b>Net Increase In Cash And Cash Equivalents (A + B + C)</b>	<b>(40.81)</b>	<b>(944.49)</b>
<b>Cash And Cash Equivalents beginning of the Period</b>	<b>64.17</b>	<b>959.84</b>
<b>Cash And Cash Equivalents ending of the Period</b>	<b>23.36</b>	<b>15.36</b>

**Notes :**

1. The above Cash flow statement has been prepared under the indirect method set out in Accounting Standard-3, "Cash Flow Statement" notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules 2014.

For & on behalf of Sotac Pharmaceuticals Limited



*Sharad Patel*

Sharad Patel  
Chairman & Managing Director  
Din No-07252252

Place: Ahmedabad  
Date: 29th October, 2024





**Auditor's Limited Review Report on unaudited Consolidated Financial results of Sotac Pharmaceutical Limited, for the Half Year ended September 30, 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

To,  
The Board of Directors of,  
Sotac Pharmaceutical Limited

We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of **Sotac Pharmaceutical Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the half year ended September 30, 2024 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

1. Sotac Pharmaceutical Limited ("Parent")
2. Sotac Healthcare Private Limited ("Subsidiary")
3. Sotac Lifesciences Private Limited ("Subsidiary")
4. Sotac Research Private Limited ("Subsidiary")

Based on our review conducted and procedures performed as stated in above and based on the statement provided by the Management related to parent & subsidiary, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the





recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the interim financial statements / financial information / financial results of Subsidiaries i.e. "Sotac Healthcare Private Limited" ("Subsidiary"), "Sotac Lifesciences Private Limited" ("Subsidiary") and Sotac Research Private Limited ("Subsidiary") included in the consolidated unaudited financial results, whose interim financial statements / financial information / financial results reflect total revenues of Rs.2910.74 Lakhs, total net profit/(loss) after tax of Rs.(34.80) and net cash flow of RS. 28.76 Lakhs for the half year ended September 30, 2024, respectively, as considered in the consolidated unaudited financial results, whose interim financial statements / financial information/ financial results have not been reviewed by us. These interim financial statements / financial information / financial results have been provided by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary is based solely on the reports of the Management and the procedures performed by us as stated in above.

Our conclusion on the statement is not modified in respect of the above matters.

For, Keyur Shah & Co.  
Chartered Accountants  
F.R.No. 141173W



Keyur B. Shah  
Proprietor  
M No. 153774  
UDIN: -24153774BKBOFR6322

Date: - 29/10/2024  
Place: Ahmedabad



**SOTAC PHARMACEUTICALS LIMITED**  
(Formerly known as Sotac Pharmaceuticals Private Limited)  
Plot No PF-21, Sanand GIDC-II, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad-382110  
**CONSOLIDATED STATEMENT OF UNAUDITED FINANCIAL RESULT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2024**

(INR in lakhs unless otherwise stated)

Sr no.	Particulars	Half Year ended		Year ended	
		30.09.2024 Unaudited	31.03.2024 Audited	30.09.2023 Unaudited	31.03.2024 Audited
I)	REVENUE FROM OPERATIONS	5,259.47	5,218.92	5,164.13	10,383.05
II)	OTHER INCOME	70.05	42.51	6.11	48.62
III)	TOTAL REVENUE ( I + II )	5,329.52	5,261.43	5,170.24	10,431.67
IV)	<b>EXPENSES</b>				
a)	Cost of Material Consumed	3,844.25	4,021.48	3,754.21	7,775.69
b)	Purchase of Stock-in-Trade	71.76	169.32	92.26	261.58
c)	Changes in Inventories of Finished Goods/ Work-In-Progress/ Stock in Trade	218.68	(94.48)	18.38	(76.10)
d)	Employee Benefit Expenses	163.03	193.80	205.77	399.57
e)	Finance Costs	101.44	79.57	90.77	170.34
f)	Depreciation and Amortisation Expense	148.45	171.51	138.54	310.05
g)	Other Expenses	529.79	519.48	651.29	1,170.77
	TOTAL EXPENSES (IV)	5,077.40	5,060.68	4,951.22	10,011.90
V)	PROFIT/(LOSS) BEFORE EXCEPTIONAL & EXTRAORDINARY ITEMS & TAX (III - IV)	252.12	200.75	219.02	419.77
VI)	Exceptional/Prior Period Items	(0.04)	(23.38)	-	(23.38)
VII)	PROFIT BEFORE EXTRAORDINARY ITEMS & TAX (V-VI)	252.08	177.37	219.02	396.39
VIII)	Extraordinary Items	-	-	-	-
IX)	PROFIT BEFORE TAX ( VII-VIII)	252.08	177.37	219.02	396.39
X)	TAX EXPENSE				
a)	Current Tax	77.81	115.38	97.26	212.64
b)	Deferred Tax	(2.58)	(172.53)	2.14	(170.39)
c)	Income Tax Prior Period		(3.79)		(3.79)
	Total Tax Expenses (X)	75.23	(60.94)	99.40	38.46
XI)	PROFIT / (LOSS) FOR THE PERIOD/YEAR (IX-X)	176.85	238.31	119.62	357.93
	Less: Share of Minorities In Subsidiary Companies (Loss)/Profit	(14.40)	(16.43)	(53.77)	(70.20)
XII)	Profit/(Loss) for the period	191.25	254.74	173.39	428.13
XIII)	Paidup Equity Share Capital (Face value Rs 10 each)	1,105.00	1,105.00	1,105.00	1,105.00
XIV)	Reserve & Surplus (Excluding Revaluation Reserve)				3,420.92
XVI)	EARNINGS PER EQUITY SHARE-BASIC/DILUTED				
	Basic /Diluted earnings per share (In INR) (not annualised, for the Half year ended)	1.73	2.31	1.59	3.90


**Notes:**

- [1] The consolidated unaudited financial results are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable
- [2] The above consolidated unaudited financial results for the half year ended September 30, 2024 have been prepared by the Company in accordance with Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on October 29 2024, A limited review of the above results has been carried out by the statutory auditors of the company .
- [3] The figures for the half year ended 31st March 2024 are the Balancing figures between the audited figures in respect of full financial year and audited figures in respect of first half of the financial year 2023-24.
- [4] The figures of the previous period have been re-grouped / rearranged and / or recasted wherever considered necessary.
- [5] Company is mainly engaged in manufacturing of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment hence segment reporting is not applicable to Company.
- [6] The Status of investor's complaints during the half year ended on September 30, 2024 as under:-

Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed during the period	Nil
Complaints resolved at the end of the period	Nil

[7] List of the Entities Consolidated in the Statement:

Name of the Subsidiaries Companies	% of Holding as on 30-09-2024	Voting Power Either Directly or Indirectly through Subsidiaries
Sotac Healthcare Private Limited	71.00	Directly
Sotac Research Private Limited	100.00	Directly
Sotac Lifesciences Private Limited	55.77	Directly



For & on behalf of Sotac Pharmaceuticals Limited

*Sharad Patel*  
Sharad Patel  
DIN:07252252  
Chairman & Managing Director

Place : Ahmedabad  
Date : 29th October '24

**SOTAC PHARMACEUTICALS LIMITED**  
(Formerly known as Sotac Pharmaceuticals Private Limited)  
Plot No PF-21, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad-382110  
**UNAUDITED CONSOLIDATED BALANCE SHEET AS AT 30TH SEPTEMBER, 2024**

Particulars	(Amount in Lakhs)	
	As at 30th September,2024	As at 31st March,2024
<b>I. EQUITY AND LIABILITIES</b>		
<b>Share Holder's Fund</b>		
(a) Share Capital	1,105.00	1,105.00
(b) Reserves and Surplus	3,610.50	3,420.92
<b>Total Equity</b>	<b>4,715.50</b>	<b>4,525.92</b>
Minority Interest	378.03	406.95
<b>Non-Current Liabilities</b>		
(a) Long-Term Borrowings	1,140.48	1,213.11
(b) Long Term Provisions	17.16	13.71
<b>Total Non-Current Liabilities</b>	<b>1,157.64</b>	<b>1,226.82</b>
<b>Current Liabilities</b>		
(a) Short-Term Borrowings	1,658.28	1,272.77
(b) Trade Payable		
i) Total outstanding dues of micro enterprise and small enterprise	1,738.63	1,429.38
ii) Total outstanding dues other than micro enterprise and small enterprise	1,560.20	1,459.99
(c) Other Current Liabilities	206.65	133.15
(d) Short-Term Provisions	136.14	77.71
<b>Total Current Liabilities</b>	<b>5,299.90</b>	<b>4,373.00</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>11,551.07</b>	<b>10,532.69</b>
<b>II.ASSETS</b>		
<b>Non-Current Assets</b>		
(a) Property, Plant & Equipment & Intangible Assets		
(i) Property, Plant & Equipment	3,727.63	3,359.50
(ii) Intangible Assets	2.37	1.30
(iii) Capital work In -Progress	862.07	512.43
(iv) Goodwill on Consolidation	190.60	190.13
(b) Non-Current Investments	617.86	209.61
(c) Deferred Tax Assets (Net)	145.24	142.66
(d) Long Term Loans and Advances	53.30	52.52
<b>Total Non-Current Assets</b>	<b>5,599.07</b>	<b>4,468.15</b>
<b>Current Assets</b>		
(a) Inventories	1,642.10	1,801.00
(b) Trade Receivables	2,813.34	2,628.77
(c) Cash and Cash Equivalents	52.12	341.78
(d) Short-Term Loans And Advances	100.82	16.80
(e) Other Current Assets	1,343.62	1,276.19
<b>Total Current Assets</b>	<b>5,952.00</b>	<b>6,064.54</b>
<b>TOTAL ASSETS</b>	<b>11,551.07</b>	<b>10,532.69</b>

For, Sotac Pharmaceuticals Limited



*Sharad Patel*

Sharad Patel  
DIN:07252252  
Chairman & Managing Director


Place: Ahmedabad  
Date: 29th October '24



**SOTAC PHARMACEUTICALS LIMITED**  
(Formerly known as Sotac Pharmaceuticals Private Limited)  
Plot No PF-21, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad-382110  
**Unaudited Cash Flow Statement for the Half year ended on 30th September ,2024**

(Amount in Lakhs)

Particulars	For the Period ended 30th September,2024	For the Period ended 30th September,2023
<b>Cash Flow from Operating Activities</b>		
Net Profit before tax paid	252.08	219.02
<b>Adjustments for :</b>		
Depreciation and amortization	148.45	138.54
Interest income	(29.70)	(1.13)
Provision for Gratuity	2.50	1.69
Finance Cost	101.44	90.77
Prior Period Item		(229.42)
Adjustment Related to IPO Expense and Deffered Government Grants	(1.67)	
<b>Operating profit before working capital changes (A)</b>	<b>473.09</b>	<b>219.46</b>
<b>Adjustment for Changes in Working Capital :</b>		
Changes in Trade Payables	409.46	288.40
Changes in Other Current Liabilities	73.50	(339.23)
Changes in Short term Provisions	(0.07)	5.47
Changes in Inventories	158.90	(339.30)
Changes in Trade Receivables	(184.57)	(1,267.01)
Changes in Short Term Loans and Advances	(84.02)	(0.80)
Changes in Other Current Assets	(67.42)	(114.36)
<b>Operating profit after working capital changes (B)</b>	<b>305.78</b>	<b>(1,766.83)</b>
<b>Cash generated from Operations (A + B)</b>	<b>778.87</b>	<b>(1,547.37)</b>
Taxes paid ( net of refund)	(18.35)	(159.47)
<b>Net Cash generated from Operations ( A )</b>	<b>760.52</b>	<b>(1,706.84)</b>
<b>Cash Flow from Investing Activities</b>		
Addition in Propery, Plant and Equipments and Intagible Assets	(518.09)	(1,027.36)
Disposals Of Propery, Plant and Equipments And Intagible Assets	0.43	
Changes in Capital Work in Progress	(349.64)	(155.66)
Changes in of Loans and advacnes	(0.78)	(178.45)
Chnages In Non Current Investments	(408.25)	
Interest income	29.70	1.13
<b>Net Cash generated / ( used ) in Investing Activities ( B )</b>	<b>(1,246.63)</b>	<b>(1,360.34)</b>



**SOTAC PHARMACEUTICALS LIMITED**  
**(Formerly known as Sotac Pharmaceuticals Private Limited)**  
**Plot No PF-21, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad-382110**  
**Unaudited Cash Flow Statement for the Half year ended on 30th September ,2024**

(Amount in Lakhs)

Particulars	For the Period ended 30th September,2024	For the Period ended 30th September,2023
<b>Cash Flow from Financing Activities</b>		
Issued Share against Share Application Money received	-	(947.05)
Proceeds from Issue of New Equity Share_Securities Premium	-	3,030.00
Changes In Minority Interest	(15.00)	485.00
Changes in Long Term Borrowings	(72.63)	24.93
Changes in of Short term Borrowings	385.51	(127.07)
Short term Advance		(430.00)
Finance Cost	(101.44)	(90.77)
Proceeds from Issue of New Equity Share	-	300.00
<b>Net Cash Used in Financing Activities ( C )</b>	<b>196.45</b>	<b>2,245.04</b>
<b>Net Changes in Cash and Cash Equivalents ( A + B + C )</b>	<b>(289.66)</b>	<b>(822.13)</b>
<b>Cash and Cash Equivalents beginning of the Period</b>	<b>341.78</b>	<b>968.16</b>
<b>Cash and Cash Equivalents ending of the Period</b>	<b>52.12</b>	<b>146.03</b>

**Notes :**

**As per our attached report of even date**

1. The above Cash flow statement has been prepared under the indirect method set out in Accounting Standard-3, "Cash Flow Statement" notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules 2014.



For, Sotac Pharmaceuticals Limited

*Sharad Patel*

Sharad Patel

DIN:07252252

Chairman & Managing Director

Place: Ahmedabad

Date: 29th October '24